Putney, Inc. Enters the $175M Annual Veterinary NSAID Market

Makes Treatment More Affordable to Pet Owners PORTLAND, Maine, June 23 /PRNewswire/ -- Putney, Inc., a pharmaceutical company focused on the development of generic drugs for pets, has launched carprofen caplets, a bioequivalent generic version of the canine medication Rimadyl(R) caplets. Putn...

Vitamin D With NSAID Drugs May Prevent Prostate Cancer

A low dose of Vitamin D with non-steroidal anti- inflammatory drugs may prevent the growth of prostate cancer cells, says a study.// David Feldman and other researchers at Stanford University studied the effects of using calcitrol, a form of Vitamin D, combined with an over-the-counter anti-in...

Nuvo Announces 2009 second quarter financial results

...ug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid, a topical nsaid used for the treatment of osteoarthritis of the knee. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and ...

AlphaRx Unveils its China Strategy

...ether with its local partners, plans to develop adjuvant vaccines to treat influenza, such as H5N1 and H1N1 strains. AlphaRx currently has a topical nsaid awaiting near-term registration in China and is developing a second product - GAI-122 - an injectable nanoemulsion, in collaboration with Gaia BioPhar...

Study demonstrates the anti-inflammatory properties of pine bark extract

...an effect on generation of the COX-1 enzyme, thus the potential for typical nsaid side effects is defied. While Pycnogenol is not a COX-2-specific inhibitor... as the kidneys, where it has important physiologic functions. "Standard nsaid medications reduce the production of prostaglandins by COX enzymes for lowe...

Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX

...an effect on generation of the COX-1 enzyme, thus the potential for typical nsaid side effects is defied. While Pycnogenol(R) is not a COX-2-specific inhibi...e kidneys, where it has important physiologic functions. "Standard nsaid medications reduce the production of prostaglandins by COX enzymes for lowe...

New research to reduce drug side-effects

...lands, Germany and Italy. The researchers will use the data to create a variety of decision models to help doctors prescribe the most suitable type of nsaid for a particular patient and lower the risk of unwanted gastrointestinal or cardiovascular side-effects. The University of Nottingham is working wi...

Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment

...ransdel. Moreover, the Company expects that Ketotransdel, if approved by the U.S. Food and Drug Administration ("FDA"), could become the first topical nsaid cream product in the U.S. for acute pain management. Also, the Company intends to pursue FDA approval of Ketotransdel for other indications, such as ...

Painkillers May Be Good for the Prostate

... found that regular use of NSAIDs yielded PSA levels 10 percent lower than in men who didn't use them. St. Sauver's study found lower PSA levels among nsaid users in her study as well. Men taking acetaminophen also were included in Singer's study, and they had about the same reduction in PSA levels. Bu...

Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR(TM) (diclofenac potassium) Liquid Filled Capsules

...said Gary A. Shangold, Chief Medical Officer of Xanodyne. "It is the first nsaid to be approved based on the demonstration of safety and efficacy in two wel...he United States. It will also be the first and only prescription strength nsaid for oral administration available for the U.S. market in a liquid-filled so...

More>>

NSAID in Medical Technology

Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use

Leading Medical Associations Collaborate to Improve Patient Safety WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- The American College of Cardiology in collaboration with the American College of Gastroenterology and the American Heart Association today released consensus guidelines outlining ...

Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain

...tics reports, these effects would equate to the 15th most common cause of death in the U.S. Studies have shown that less than 30 percent of high-risk nsaid patients are co-prescribed a gastro-protective agent in combination with their NSAID. In addition, patient adherence to a regimen of separate pain an...

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

...with naproxen. Naproxen is widely regarded as the nsaid with the most favorable cardiovascular safety prof... LT-NS001 is pharmacologically inactive as an nsaid in the GI tract, but once absorbed into the bloods...ts of treating ulcer complications associated with nsaid use exceed $4 billion a year. Serious NSAID-induce...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

...uld tell their doctor about all their medicines, including those for migraine, to avoid a potentially life-threatening condition. Taking Cymbalta with nsaid pain relievers, aspirin, or blood thinners may increase bleeding risk. They also should talk to their doctor about their alcohol consumption. Patients...

Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

...rts, these effects would equate to the 15th most common cause of death in the United States. Studies have shown that less than 30 percent of high-risk nsaid patients are co-prescribed a gastro-protective agent in combination with their NSAID. In addition, patient adherence to a regimen of separate pain and...

Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain

...d tell their doctor about all their medicines, including those for migraine, to avoid a potentially life-threatening condition. Taking Duloxetine with nsaid pain relievers, aspirin, or blood thinners may increase bleeding risk. Patients should consult with their doctor before stopping Duloxetine or changin...

Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream

...tatistical significance in its primary efficacy endpoint, nor in several secondary endpoints. The effect witnessed did not measure up to other topical nsaid (non-steroidal anti-inflammatory drug) products already approved or currently in development in the US. This study confirmed the safety of th...

Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference

...portant that the professional rheumatology community be aware of what we believe is the strongest clinical efficacy and safety evidence of any topical nsaid formulation for the treatment of osteoarthritis. We believe that this data supports the conclusion that Pennsaid, once approved, will be the best-in-c...

Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001

...ointestinal (GI) side effects are a significant safety problem," said Lutz Giebel, Chairman of Logical Therapeutics. Published studies have shown that nsaid use is responsible for 15-60% of hospital admissions for GI bleeding, amounting to approximately 100,000 hospitalizations and 10,000-20,000 deaths ann...

Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis

...oup. Patients were supplemented with 150 mg Pycnogenol(R) or placebo per day over a period of three months. They were allowed to continue taking their nsaid or analgesics prescribed before the study but had to record every pill taken. The established Western Ontario McMaster questionnaire for joint functio...

NSAID in Medical Dictionary

Ulcer

...about ulcers . ... Do you want an ulcer ? ... What Causes an Ulcer ? ... An ulcer is an eroded area of skin or mucous membrane. ... Chronic nsaid users have 40 times the risk of developing a gastric ulcer as nonusers. ... WebMD explores peptic ulcer disease, including its causes and ...

NSAID in Biological News

The quest for specific anti-inflammatory treatment

... is working on analogues of the C1P molecule. Today two types of anti-inflammatory pharmaceutical drugs are available: steroids and those known as nsaid (Non-steroidal anti-inflammatory drugs). This second type are the most used, have fewer side-effects but they have an effect over a wider spectrum, i....

COX-2 inhibitors significantly reduce risk of cancer

...mental Health in The Ohio State University College of Medicine and lead author of the study. The results come from a larger, case-control study of nsaid use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, ant...

NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses

...lack of tumor suppressor genes as well as poor diet," says the lead author, WanCai Yang, M.D., an assistant professor of medicine. While the drug is a nsaid (non-steroidal anti-inflammatory drug) and a COX-2 inhibitor, Yang believes its chemoprotective effects come via novel pathways that affect p21 expres...

FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

...non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective nsaid medications. A list of these products is available on the Internet at http://www.fda.gov/cder/drug/infopage/cox2/default.htm. "Today's actions prote...

NSAID in Biological Technology

AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use

- Webinar on June 9 to discuss the prevalence and prevention of NSAID-induced ulcers available at www.connecttoprotect.com - BETHESDA, Md. and CHICAGO, June 1 /PRNewswire/ -- The American Gastroenterological Association (AGA) Institute and Horizon Therapeutics, Inc. today launched C...

Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water

...ysis of these drugs when present, at even low levels, in natural water samples." SupelMIP was developed for confirmation and quantitation of nsaid drugs in water samples. The SPE phase has been developed for multi-residue extraction of NSAIDs and has been validated for ibuprofen, diclofenac, napr...

Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia

...ny with several developmental candidates in the areas of cancer, inflammation and novel antibiotics. The lead candidate, CG100649 is a next generation nsaid with high safety and efficacy, which recently completed phase IIa of 248 patients for osteoarthritis in Europe. CG200745 is an oral/IV HDAC inhibitor ...

Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug

... is a prodrug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug (NSAID). Naproxen is widely regarded as the nsaid with the most favorable cardiovascular safety profile among all of the drugs in this class. In pre-clinical studies in rats and dogs, LT-NS001 was sho...

Horizon Therapeutics Announces Corporate Relocation to the Chicago Area

...oprietary formulation of ibuprofen combined with famotidine in a single pill currently in Phase 3 clinical trials. Because approximately 25 percent of nsaid users may develop stomach ulcers, HZT-501 may offer patients effective pain relief with the confidence of GI-protection. Horizon expects to have data ...

Transdel Pharmaceuticals Closes $4 Million Financing

...mand for topical pain management products such as Ketotransdel(TM). If approved by the FDA, Ketotransdel(TM) has the potential to be the first topical nsaid cream product in the United States for acute pain management. About Transdel Pharmaceuticals, Inc. Transdel Pharmaceuticals, Inc. (OTC Bulletin Bo...

Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

...033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the nsaid diclofenac topically in patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and ...

Pharmos Corporation Reports 2008 First Quarter Results

...033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the nsaid diclofenac topically in patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and ...

Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium

...ions if left untreated. As there is no way to predict which patients might develop inflammatory complications, doctors often prescribe steroids and/or nsaid drops to prevent it. Most often, inflammation lasts a relatively short time, though severe forms can persist for a longer period of time. About Dure...

Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management

...herapy due to flushing, the most commonly reported side effect of SIMCOR and niacin-based therapies. Flushing can be minimized by taking aspirin or an nsaid 30 minutes prior to taking the medication at bedtime. Flushing may subside over several weeks of consistent SIMCOR use. "With SIMCOR, doctors now ha...